ISSN 1662-4009 (online)

ey0021.10-12 | New Biomarkers | ESPEYB21

10.12. A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes

G Sebastiani , GE Grieco , M Bruttini , S Auddino , A Mori , M Toniolli , al. et

Brief Summary: Circulating microRNAs (miRNA) were measured using multiplatform sequencing in longitudinal samples from 262 individuals with newly diagnosed type 1 diabetes (T1D) enrolled in the INNODIA Natural History Study. A set of miRNAs located within the T1D susceptibility chromosomal locus 14q32 distinguished 2 groups of T1D: those with higher miRNA expression showed better glycemic outcomes and immunomics profile.MicroRNAs (miRNAs) are a class of ...

ey0015.11-13 | Adipose tissue – a main source of miRNAs | ESPEYB15

11.13 Adipose-derived circulating miRNAs regulate gene expression in other tissues

T Thomou , M Mori , J Dreyfuss , M Konishi , M Sakaguchi , C Wolfrum , T Nageswara Raa , J Winnay , R Garcia-Martin , S Grinspoon , P Gorden , R Kahn

To read the full abstract: Nature 2017, 542, 450–455Adipose tissue is no longer considered a passive energy store. Instead, it is well established as an important endocrine contributor. Here, the authors comprehensively show that the function of the adipose tissue as an endocrine organ is not limited to classical adipokines, but also includes miRNAs and maybe other non-coding RNAs. This study...

ey0020.2-7 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.7. Weekly somapacitan is effective and well tolerated in children with GH deficiency: The randomized phase 3 REAL4 trial

BS Miller , JC Blair , MH Rasmussen , A Maniatis , RJ Kildemoes , J Mori , M Polak , RB Bang , V Bottcher , S Stagi , R Horikawa

Brief summary: This multicenter, randomized, controlled, phase 3 study compared the effects of long-acting GH (Somapacitan; 0.16 mg/kg/wk) with daily GH (Norditropin; 0.034 mg/kg/d), in GHD children. The trial was conducted over 52 weeks, followed by an ongoing 3-year single-group extension period. Similar efficacy and safety for somapacitan compared to daily GH was demonstrated over 52 weeks of treatment.Long-acting growth hormone (LAGH) formulations ha...